SCHEMBL20992174

SCHEMBL20992174

CCC[C@H](C)C(N)(O)C(C)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
CYP3A4 P08684 2/20 0.39
NFKB1 P19838 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CHRM1 P11229 1/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
METAP1 P53582 2/20 0.33
GRIK1 P39086 1/20 0.32
SLC1A3 P43003 1/20 0.32
SLC1A2 P43004 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8727941 0.82 CHRM1 (0.41) TSHRCYP3A4NFKB1NPSR1CHRM1
SCHEMBL1782839 0.77 CHRM1 (0.36) TSHRCYP3A4NFKB1NPSR1CHRM1
SCHEMBL20854296 0.76 CHRM1 (0.44) TSHRCYP3A4NFKB1NPSR1CHRM1
Acetic Acid SCHEMBL5574320 0.76 CHRM1 (0.39) TSHRCYP3A4NFKB1NPSR1CHRM1
SCHEMBL20854183 0.76 CHRM1 (0.44) TSHRCYP3A4NFKB1NPSR1CHRM1
SCHEMBL4609302 0.74 CHRM1 (0.37) TSHRCYP3A4NFKB1NPSR1CHRM1
SCHEMBL13684296 0.74 CHRM1 (0.37) TSHRCYP3A4NFKB1NPSR1CHRM1
SCHEMBL9869598 0.73
SCHEMBL28936397 0.73 CHRM1 (0.41) TSHRCYP3A4NFKB1NPSR1CHRM1
SCHEMBL9767794 0.73 CHRM1 (0.36) TSHRCYP3A4NFKB1NPSR1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287301-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2019-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287301-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders CFD, F12, F3 TSHR 744/4885CYP3A4 277/4885NFKB1 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.